Neoadjuvant therapy impact in early pancreatic cancer: “bioborderline” vs. “non-bioborderline”

BACKGROUNDS/AIMS: To analyze the results of the neoadjuvant treatment of patients in our center with early pancreatic cancer. METHODS: Eighty-four patients with early pancreatic cancer (I–II) were included, of which 59 were considered “bioborderline” (carbohydrate antigen [CA] 19-9 > 37 U/L), and...

Descripción completa

Detalles Bibliográficos
Autores principales: Taboada, Alvaro Gregorio Morales, Lominchar, Pablo Lozano, Martínez, María Fernández, García-Alfonso, Pilar, Martin, Andrés Muñoz, Asencio, Jose Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Hepato-Biliary-Pancreatic Surgery 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9721251/
https://www.ncbi.nlm.nih.gov/pubmed/36372553
http://dx.doi.org/10.14701/ahbps.22-023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9721251/
https://www.ncbi.nlm.nih.gov/pubmed/36372553
http://dx.doi.org/10.14701/ahbps.22-023

Ejemplares similares